Skip to main content
. 2016 Nov 7;7(48):79943–79955. doi: 10.18632/oncotarget.13161

Figure 4. Kaplan-Meier analysis of PD-L1 DNA methylation in prostate cancer patients (validation cohort).

Figure 4

Patient samples were stratified into mPD-L1low (grey) and mPD-L1high (black) according an optimized cut-off. Kaplan-Meier analysis of PD-L1 DNA methylation showed a better prognosis for the mPD-L1low patient subgroup. Univariate Cox proportional hazard analyses conducted using an optimized cut-off corroborated the prognostic value of mPD-L1.